source
- FDA considers two new executive posts and approves first-of-its-kind early drug and ketone‑glucose wearableThe Health and Human Services department is reportedly evaluating the creation of two additional senior positions within the FDA, a step that could increase agency oversight. In recent approvals,…
- AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart diseaseResults published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.